John H. Proffitt

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

Gerard Lozanski, Nyla A. Heerema, Ian W. Flinn et al. · Blood · 2004 · 403 citations · Full text

5-Methylcytosine is not detectable in Saccharomyces cerevisiae DNA.

John H. Proffitt, James Davie, David Swinton et al. · Molecular and Cellular Biology · 1984 · 174 citations

Epigenetic Change, Genetics, Dna Methylation +20

Diagnostic utility of fluorescence <i>in situ</i> hybridization in mantle‐cell lymphoma

Ellen D. Remstein, Paul J. Kurtin, Ismael Buño et al. · British Journal of Haematology · 2000 · 115 citations

Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma

Soraya Wuillème, Nelly Robillard, Laurence Lodé et al. · Leukemia · 2004 · 115 citations

Hematological Malignancy, Tumor Biology, Chromatin +11

Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.

John C. Byrd, Lisa Smith, Marcy L. Hackbarth et al. · PubMed · 2003 · 91 citations

Chronic Lymphocytic Leukemia, Mixed-phenotype Acute Leukemia, Genetics +16